Table 3 Propensity score analysis results 1: Survival impact across quintiles based on the propensity to receive chemotherapy among patients with metastatic non-small cell lung cancer, who survived at least 3 months after their cancer diagnosis (n = 7,879)
From: The effect on survival of continuing chemotherapy to near death
Analysis | Variables | HR | (95%CI) | P-value |
|---|---|---|---|---|
Stratified analysis | Â | Â | Â | Â |
Lowest quintile of PS* | No chemotherapy | 1.00 | - | - |
| Â | Chemotherapy | 0.82 | (0.73, 0.93) | < 0.01 |
Second quintile of PS | No chemotherapy | 1.00 | - | - |
| Â | Chemotherapy | 0.77 | (0.69, 0.85) | < 0.001 |
Third quintile of PS | No chemotherapy | 1.00 | - | - |
| Â | Chemotherapy | 0.81 | (0.74, 0.90) | < 0.001 |
Fourth quintile of PS | No chemotherapy | 1.00 | - | - |
| Â | Chemotherapy | 0.85 | (0.77, 0.93) | < 0.01 |
Highest quintile of PS†| No chemotherapy | 1.00 | - | - |
| Â | Chemotherapy | 0.73 | (0.66, 0.81) | < 0.001 |
Multiple Cox regression adjustment using the PS | No chemotherapy | 1.00 | - | - |
| Â | Chemotherapy | 0.76 | (0.71, 0.82) | < 0.001 |